Heartflow (NASDAQ:HTFL) CFO Sells $332,199.20 in Stock

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 6,640 shares of Heartflow stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $50.03, for a total transaction of $332,199.20. Following the sale, the chief financial officer directly owned 214,503 shares of the company’s stock, valued at $10,731,585.09. This trade represents a 3.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

• On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The stock was sold at an average price of $49.69, for a total transaction of $1,368,462.60.
• On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The stock was sold at an average price of $50.60, for a total value of $297,325.60.

Heartflow Trading Up 9.7%

HTFL opened at $49.88 on Friday. The stock has a market cap of $4.34 billion and a price-to-earnings ratio of -27.26. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $51.78. The stock has a fifty day moving average price of $35.52 and a 200 day moving average price of $30.78.

Heartflow (NASDAQ:HTFL) last issued its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The company had revenue of $64.08 million for the quarter. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. As a group, sell-side analysts forecast that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HTFL has been the topic of several recent research reports. Benchmark reaffirmed a “buy” rating on shares of Heartflow in a research report on Friday, August 14th. Wells Fargo & Company increased their price target on shares of Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. Canaccord Genuity Group upped their price objective on shares of Heartflow from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Finally, UBS Group began coverage on shares of Heartflow in a research report on Wednesday. They set a “neutral” rating and a $55.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.88.

Institutional Investors Weigh In On Heartflow

Large investors have recently added to or reduced their stakes in the stock. XXEC Inc. acquired a new position in Heartflow during the second quarter valued at approximately $2,524,764,000. BlackRock Inc. acquired a new stake in shares of Heartflow in the second quarter worth $152,502,000. Wellington Management Group LLP bought a new stake in shares of Heartflow during the 3rd quarter worth $164,263,000. Bamco Inc. NY bought a new stake in shares of Heartflow during the 2nd quarter worth $94,625,000. Finally, Jupiter Topco LLC acquired a new position in Heartflow in the 2nd quarter valued at $70,983,000.

Heartflow Company Profile

Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.

The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFR^CT).